Clinical Trial: A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839872) titled 'A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma' on Jan. 21.

Brief Summary: To assess the efficacy and safety of pirtobrutinib in participants with CLL/SLL who have progressed on first-line treatment with acalabrutinib.

Study Start Date: June 30, 2025

Study Type: INTERVENTIONAL

Condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Intervention: DRUG: Pirtobrutinib

Patients will receive pirtobrutinib orally with dosing schedule as prescribed

DRUG: A...